Pharmacokinetics and pharmacodynamics of drug‒drug interactions in hospitalized older adults treated with direct oral anticoagulants.
CYP3A4
Direct oral anticoagulant
Drug-drug interaction
Older adults
P-glycoprotein
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
received:
31
01
2024
accepted:
26
04
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
22
5
2024
Statut:
epublish
Résumé
Polypharmacy is a frequent situation in older adults that increases the risk of drug-drug interactions (DDIs), both pharmacokinetic (PK) and pharmacodynamic (PD). Direct oral anticoagulants (DOACs) are frequently prescribed in older adults, mainly because of the high prevalence of atrial fibrillation (AF). DOACs are subject to cytochrome P450 3A4 (CYP3A4)- and/or P-glycoprotein (P-gp)-mediated PK DDIs and PD DDIs when co-administered with drugs that interfere with platelet function. The aim of our study was to assess the prevalence of DDIs involving DOACs in older adults and the associated risk factors at admission and discharge. This was a cross-sectional study conducted in an acute geriatric unit between January 1, 2018 and December 31, 2022, including patients over 75 years of age treated with DOACs at admission and/or discharge, for whom a comprehensive collection of co-medications was performed. From 909 hospitalizations collected, the prevalence of PK DDIs involving DOACs was 16.9% at admission and 20.7% at discharge, and the prevalence of PD DDIs was 20.7% at admission and 20.2% at discharge. Factors associated with DDIs were bleeding history [adjusted odds ratio (ORa) 1.74, 95% confidence interval (CI) 1.13-2.68], number of drugs > 6 (ORa 2.54, 95% CI 1.88-3.46) and reduced dose of DOACs (ORa 0.39, 95% CI 0.28-0.54) at admission and age > 87 years (ORa 0.74, 95% CI 0.55-0.99), number of drugs > 6 (ORa 2.01, 95% CI 1.48-2.72) and reduced dose of DOACs (ORa 0.41, 95% CI 0.30-0.57) at discharge. This study provides an indication of the prevalence of DDIs as well as the profile of DDIs and patients treated with DOACs.
Identifiants
pubmed: 38776005
doi: 10.1007/s40520-024-02768-w
pii: 10.1007/s40520-024-02768-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Informations de copyright
© 2024. The Author(s).
Références
Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17:1185–1196. https://doi.org/10.1080/14740338.2018.1546841
doi: 10.1080/14740338.2018.1546841
pubmed: 30540223
Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC et al (2018) Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 9:CD008165. https://doi.org/10.1002/14651858.CD008165.pub4
doi: 10.1002/14651858.CD008165.pub4
pubmed: 30175841
Montamat SC, Cusack B (1992) Overcoming problems with polypharmacy and drug misuse in the elderly. Clin Geriatr Med 8:143–158
doi: 10.1016/S0749-0690(18)30503-2
pubmed: 1576572
Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33. https://doi.org/10.1016/j.clpt.2003.09.012
doi: 10.1016/j.clpt.2003.09.012
pubmed: 14749689
Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007
doi: 10.1016/j.pharmthera.2012.12.007
pubmed: 23333322
Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV et al (2019) REPOSI investigators. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med 65:51–57. https://doi.org/10.1016/j.ejim.2019.05.002
doi: 10.1016/j.ejim.2019.05.002
pubmed: 31084979
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al (2014) Worldwide epidemiology of atrial fibrillation: a global burden of Disease 2010 study. Circulation 129:837–847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119
doi: 10.1161/CIRCULATIONAHA.113.005119
pubmed: 24345399
Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA et al (2016) ARISTOTLE investigators. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1:673–681. https://doi.org/10.1001/jamacardio.2016.1829
doi: 10.1001/jamacardio.2016.1829
pubmed: 27463942
Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC et al (2014) Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol 54(08):917–927. https://doi.org/10.1002/jcph.288
doi: 10.1002/jcph.288
pubmed: 24668660
Mueck W, Schwers S, Stampfuss J (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 11:1. https://doi.org/10.1186/1477-9560-11-10
doi: 10.1186/1477-9560-11-10
Kubitza D, Becka M, Roth A, Mueck W (2013) The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor xa inhibitor. J Clin Pharmacol 53:249–225. https://doi.org/10.1002/jcph.5
doi: 10.1002/jcph.5
pubmed: 23381840
Voukalis C, Lip GY, Shantsila E (2016) Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol 12:1445–1461. https://doi.org/10.1080/17425255.2016.1225037
doi: 10.1080/17425255.2016.1225037
pubmed: 27535163
Li A, Li MK, Crowther M, Vazquez SR (2020) Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thromb Res. 194:240–245. https://doi.org/10.1016/j.thromres .
Li A, Li MK, Crowther M, Vazquez SR (2020) Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thromb Res. 194:240–245. https://doi.org/10.1016/j.thromres .
Gronich N, Stein N, Muszkat M (2021) Association between Use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther 110:1526–1536. https://doi.org/10.1002/cpt.2369
doi: 10.1002/cpt.2369
pubmed: 34287842
pmcid: 9290518
Thompson LE, Davis BH, Narayan R, Goff B, Brown TM, Limdi NA (2023) Personalizing direct oral anticoagulant therapy for a Diverse Population: role of race, kidney function, drug interactions, and Pharmacogenetics. Clin Pharmacol Ther 113:585–599. https://doi.org/10.1002/cpt.2714
doi: 10.1002/cpt.2714
pubmed: 35857814
Sanborn D, Sugrue A, Amin M, Mehta R, Farwati M, Deshmukh AJ et al (2022) Outcomes of direct oral anticoagulants co-prescribed with common interacting medications. Am J Cardiol 162:80–85. https://doi.org/10.1016/j.amjcard.2021.09.025
doi: 10.1016/j.amjcard.2021.09.025
pubmed: 34756422
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126. https://doi.org/10.1111/jth.13140
doi: 10.1111/jth.13140
pubmed: 26764429
Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202–204. https://doi.org/10.1111/j.1538-7836.2009.03678.x
doi: 10.1111/j.1538-7836.2009.03678.x
pubmed: 19878532
Sun GW, Shook TL, Kay GL (1996) Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 49:907–916. https://doi.org/10.1016/0895-4356(96)00025-x
doi: 10.1016/0895-4356(96)00025-x
pubmed: 8699212
Harrell FE, Lee KL, Matchar DB, Reichert TA (1985) Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 69:1071–1077
pubmed: 4042087
Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA, Non-Vitamin K (2017) Antagonist oral anticoagulant dosing in patients with Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol 69:2779–2790. https://doi.org/10.1016/j.jacc.2017.03.600
doi: 10.1016/j.jacc.2017.03.600
pubmed: 28595692
Dent E, Hoogendijk EO, Visvanathan R, Wright ORL (2019) Malnutrition Screening and Assessment in Hospitalised Older people: a review. J Nutr Health Aging 23:431–441. https://doi.org/10.1007/s12603-019-1176-z
doi: 10.1007/s12603-019-1176-z
pubmed: 31021360
O’Sullivan ED, Hughes J, Ferenbach DA (2017) Renal aging: causes and consequences. J Am Soc Nephrol 28:407–420. https://doi.org/10.1681/ASN.2015121308
doi: 10.1681/ASN.2015121308
pubmed: 28143966
Kok RM, Reynolds CF 3rd (2017) Management of Depression in older adults: a review. JAMA 317:2114–2122. https://doi.org/10.1001/jama.2017.5706
doi: 10.1001/jama.2017.5706
pubmed: 28535241
Carlisle MA, Fudim M, DeVore AD, Piccini JP (2019) Heart failure and Atrial Fibrillation, like fire and fury. JACC Heart Fail 7:447–456. https://doi.org/10.1016/j.jchf.2019.03.005
doi: 10.1016/j.jchf.2019.03.005
pubmed: 31146871
Douxfils J, Ageno W, Samama CM et al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16(2):209–219. https://doi.org/10.1111/jth.13912
doi: 10.1111/jth.13912
pubmed: 29193737
Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A et al (2013) Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 18:601–610
pubmed: 24516494
pmcid: 3897029
Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Marín-Gil R, Villacorta-Linaza P (2012) Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 34:807–817. https://doi.org/10.1007/s11096-012-9697-0
doi: 10.1007/s11096-012-9697-0
pubmed: 22965222
Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153–158. https://doi.org/10.1080/02813430310001806
doi: 10.1080/02813430310001806
pubmed: 14531506
Bellosta S, Corsini A (2018) Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf 17:25–37. https://doi.org/10.1080/14740338.2018.1394455
doi: 10.1080/14740338.2018.1394455
pubmed: 29058944
Williams S, Miller G, Khoury R, Grossberg GT (2019) Rational deprescribing in the elderly. Ann Clin Psychiatry 31:144–152
pubmed: 31046036
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373–498. https://doi.org/10.1093/eurheartj/ehaa612
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
Volgman AS, Nair G, Lyubarova R, Merchant FM, Mason P, Curtis AB et al (2022) Management of Atrial Fibrillation in patients 75 years and older: JACC state-of-the-art review. J Am Coll Cardiol 79:166–179. https://doi.org/10.1016/j.jacc.2021.10.037
doi: 10.1016/j.jacc.2021.10.037
pubmed: 35027110
Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, ROCKET AF Steering Committee and Investigators et al (2014) Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm 11:925–932. https://doi.org/10.1016/j.hrthm.2014.03.006
doi: 10.1016/j.hrthm.2014.03.006
pubmed: 24833235
pmcid: 4035424
Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, ARISTOTLE Committees and Investigators (2014) Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2014;64:1541–1550. https://doi.org/10.1016/j.jacc.2014.07.967
Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 49:636–643. https://doi.org/10.1007/s11239-020-02037-3
doi: 10.1007/s11239-020-02037-3
pubmed: 31925665
Foulon-Pinto G, Lafuente-Lafuente C, Jourdi G, Guen JL, Tall F, Puymirat E et al (2023) Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban concentrations and Thrombin Generation profiles in NVAF very Elderly patients. Thromb Haemost 123:402–414. https://doi.org/10.1055/a-1981-1763
doi: 10.1055/a-1981-1763
pubmed: 36395818
pmcid: 10060059